<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8194">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01856504</url>
  </required_header>
  <id_info>
    <org_study_id>VICTORY</org_study_id>
    <nct_id>NCT01856504</nct_id>
  </id_info>
  <brief_title>Validation of an Intracycle CT Motion CORrection Algorithm for Diagnostic AccuracY</brief_title>
  <acronym>VICTORY</acronym>
  <official_title>Validation of an Intracycle CT Motion CORrection Algorithm for Diagnostic AccuracY: A Prospective Multicenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MDDX LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GE Healthcare</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>MDDX LLC</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate the incremental utility of SSF for individuals undergoing CCTA, with expected
      improvements in image quality and diagnostic accuracy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypothesis: Coronary CT angiography (CCTA) employing a novel intracycle motion compensation
      algorithm (SnapShot Freeze [SSF]) will be superior to CCTA without an intracycle motion
      compensation algorithm (&quot;conventional&quot; CCTA) for diagnostic accuracy and image quality.

      Scientific Basis: Preliminary study (Leipsic, Min, Journal of Cardiovascular Computed
      Tomography [in press]) of coronary CT angiograms in individuals undergoing pre-procedural
      assessment for transcatheter aortic valve replacement (n=36) demonstrate improved image
      quality of CCTA using SSF compared to CCTA not using SSF.  Importantly, individuals in this
      study did not receive heart rate slowing agents (e.g., beta blockers), and diagnostic image
      quality was substantially improved.  While not statistically powered on a per-patient basis,
      per-segment diagnostic accuracy of CCTA using SSF was superior to conventional CCTA.  These
      results are complementary to those derived from internal testing at GE Healthcare wherein
      phantom work has demonstrated improved diagnostic performance using SSF compared to
      conventional image acquisitions.

      Long-term Goal/Purpose: To demonstrate the incremental utility of SSF for individuals
      undergoing CCTA, with expected improvements in image quality and diagnostic accuracy.  If
      the aims of this study are achieved, the use of SSF for effective temporal resolution
      improvement may obviate (or reduce) the need for CT hardware for improved temporal
      resolution.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">May 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <target_duration>30 Days</target_duration>
  <primary_outcome>
    <measure>Diagnostic Accuracy</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>To compare the per-patient, per-vessel and per-segment diagnostic accuracy of CCTA with SSF to conventional CCTA, as compared to invasive quantitative coronary angiography.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic Interpretability</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>To compare the per-patient, per-vessel and per-segment diagnostic interpretability of CCTA with SSF to conventional CCTA, as compared to invasive quantitative coronary angiography.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Image quality</measure>
    <time_frame>30 day</time_frame>
    <safety_issue>No</safety_issue>
    <description>To compare the per-patient, per-vessel and per-segment quantitative image quality of CCTA with SSF to conventional CCTA, as compared to invasive quantitative coronary angiography.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Upper threshold of heart rate</measure>
    <time_frame>1 day</time_frame>
    <safety_issue>No</safety_issue>
    <description>To determine the upper threshold of heart rate below which CCTA with SSF is most effective.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incremental &amp; additive value</measure>
    <time_frame>1 day</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To determine the incremental &amp; additive value of SSF to conventional CCTA for diagnostic accuracy / diagnostic interpretability / image quality.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">218</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Coronary Arteriosclerosis</condition>
  <arm_group>
    <arm_group_label>CCTA Patient</arm_group_label>
    <description>Consenting adult patients ≥18 years of age;
Suspected but without known prior history of CAD
Not actively taking heart rate lowering agents at least 48 hours prior to study (e.g., AV nodal blockers such as beta blockers, calcium channel blockers or digoxin)
Glomerular filtration rate &gt;60 ml/min
CCTA and ICA within 1 week of each other with no interscan event (e.g., myocardial infarction or coronary revascularization)</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Consenting adult patients ≥18 years of age, Suspected but without known prior history of
        CAD, Not actively taking heart rate lowering agents at least 48 hours prior to study
        (e.g., AV nodal blockers such as beta blockers, calcium channel blockers or digoxin)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Consenting adult patients ≥18 years of age;

          2. Suspected but without known prior history of CAD

          3. Not actively taking heart rate lowering agents at least 48 hours prior to study
             (e.g., AV nodal blockers such as beta blockers, calcium channel blockers or digoxin)

          4. Glomerular filtration rate &gt;60 ml/min

          5. CCTA and ICA within 1 week of each other with no interscan event (e.g., myocardial
             infarction or coronary revascularization)

        Exclusion Criteria:

          1. Incomplete ICA or CCTA;

          2. Known CAD (prior myocardial infarction, PCI, CABG)

          3. Atrial Fibrillation

          4. Abnormal Renal Function (GFR &lt;60 ml/min)

          5. Unwilling or unable to give consent

          6. Non-cardiac illness with life expectancy &lt;1 year

          7. Concomitant participation in another clinical trial in which subject is subject to
             investigational drug or device

          8. Pregnant women

          9. Allergy to iodinated contrast agent

         10. Contraindications to nitroglycerin

         11. Systolic blood pressure ≤90 mm Hg

         12. Contraindications to β blockers or nitroglycerin
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dan Gebow, PhD</last_name>
    <phone>4152441481</phone>
    <email>dgebow@mddx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>MDDX</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dan Gebow, PhD</last_name>
      <phone>415-244-1481</phone>
      <email>dgebow@mddx.com</email>
    </contact>
    <investigator>
      <last_name>Dan Gebow, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Walter Reed Medical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Todd Villines, MD</last_name>
    </contact>
    <investigator>
      <last_name>Todd Villines, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Midwest Cardiology Associates</name>
      <address>
        <city>Independence</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Bloom, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Diagnostico Maipu</name>
      <address>
        <city>San Isidro</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Carrascosa, MD</last_name>
    </contact>
    <investigator>
      <last_name>Patricia Carrascosa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of British Columbia</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6T 1Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Grieve</last_name>
      <phone>604 682-2344</phone>
      <phone_ext>62529</phone_ext>
      <email>egrieve@providencehealth.bc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Trisha Duval</last_name>
      <phone>917 837 7911</phone>
      <email>tduval@createresearchllc.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jonathan Leipsic, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brett Heilbron, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>FACTS</name>
      <address>
        <city>Hyderabad</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ravi Bathina, MD</last_name>
    </contact>
    <investigator>
      <last_name>Daniel Friedman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Cardiologico Monzino</name>
      <address>
        <city>Monzino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniele Andreini, MD</last_name>
    </contact>
    <investigator>
      <last_name>Daniele Andreini</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Argentina</country>
    <country>Canada</country>
    <country>India</country>
    <country>Italy</country>
  </location_countries>
  <removed_countries>
    <country>Japan</country>
    <country>Australia</country>
    <country>Korea, Republic of</country>
  </removed_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 28, 2013</lastchanged_date>
  <firstreceived_date>May 15, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart Disease</keyword>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>Coronary Arteriosclerosis</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arteriosclerosis</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
